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 We present the case of a 53-year-old woman who underwent total thyroidectomy as a multinodular goiter 
treatment, which after surgery presented hypocalcemia that did not reverse with combined therapy of calciotropic 
hormones and calcium supplementation. The symptomatology remission was reached only after the prescription 
of magnesium lactate tablets. It is known that hypocalcemia is the main complication of this surgery, however, 
little is known about hypomagnesemia and its role as a cause and consequence of the imbalance in calcium 
homeostasis in this kind of patients. The clinical and biochemical evolution of the patient is evaluated, as well as 
the pathophysiology of hypocalcemia due to magnesium deficiency that involves a large number of processes 
such as renal, intestinal and bone function. 
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INTRODUCTION 
Calcium homeostasis is regulated by several metabolic 
processes that keep a plasma concentration of calcium within 
narrow limits, ranging between 8.8 and 10.4 mg/dl. In general, 
these processes are orchestrated by parathyroid hormone 
(PTH), thyroid hormone, vitamin D, calcitonin, phosphorus and 
magnesium. The role played by the latter, unlike the other 
factors involved, is poorly understood (1). 
Magnesium depletion has been associated with 
parathyroid activity deterioration and subsequent 
hypocalcemia. This phenomenon may be due to a failure in the 
production or release of PTH, reduced bone response to this 
hormone, bone resistance to vitamin D, increased calcitonin 
action or to a primary change bone crystals solubility, growth 
rate or dissolution (2). 
Patients undergoing total thyroidectomy as a treatment for 
several types of malignant or benign nodules develop 
hypocalcemia as main postsurgical complication, which is 
often accompanied by hypomagnesemia. It has been shown 
that a significant decrease in magnesium levels after surgery is 
significantly associated with the development of permanent 
hypocalcemia (3,4). 
CASE REPORT 
A 53-year-old female patient assisted to the Endocrinology 
and Internal Medicine consultation in November 2017, 
describing pain in the right hemithorax and lower limbs. Initial 
laboratories showed triglycerides of 440 mg/dl, thyroid 
ultrasound with multinodular goiter and thyroid scan with 
similar abnormalities. The fine needle biopsy revealed atypia 
of uncertain significance with follicular lesions of Hürthle cells. 
She was submitted to total thyroidectomy on April 16, 
2018. In the postoperative period, the patient presented 
hypocalcemia (6.7 mg/dl) with serum albumin of 3.5 g/dl, and 
corrected calcium of 7.1 mg/dl. The patient was treated with 5 
tablets of caltrate 600 + M every 8 hours, calcitriol 0.25 µg every 
12 hours and PTH sc 20 µg every 24 hours. Due to persistent 
hypocalcemia, 1 tablet of Limagal (magnesium lactate) 750 mg 
was added every 8 hours. 21 days later the serum calcium 
increased to 9.2 g/dl. Four weeks later the patient suspended 
the magnesium lactate, with posterior appearance of distal 
paresthesias in lower limbs with multiple involuntary muscle 
contractions. Therefore, the magnesium lactate had to be 
restored, correcting immediately the clinical manifestations. 
DISCUSSION 
The case of this patient is a clear example of what 
happened in patients undergoing thyroidectomy regarding 
their calcium levels and the management they should receive 
for the correction of the alterations. However, there is still no 
established consensus on the pathophysiology of this process, 
and although several mechanisms have been proposed, which 
will be discussed below, none fully explains the role of 
magnesium in calcium homeostasis. 
An essay published in 1973 by Reddy CR et al., which 
consisted of assessing serum calcium levels in chicks with and 
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without magnesium deficiency, points to two 
pathophysiological mechanisms: 1) Altered calcium balance 
between the extracellular environment and the bone, favoring 
displacement towards the latter. This event is evidenced by 
observing an increase in cortical bone thickness and decrease 
in lytic areas, 2) Parathyroid gland dysfunction or lack of 
response to PTH probably due to the presence of an excess of 
osteoid tissue, phenomenon that can be confirmed by high 
serum phosphate concentration (5). 
Another study conducted in dogs in 1979 by Freitag et al., 
in which the PTH response was evaluated in perfused bone 
isolated from a control population of dogs with a normal diet 
and another population fed with a reduced magnesium diet, 
showed evidence of bone resistance to this hormone, 
reinforcing what was published by Reddy et al. (2). In the study 
of Freitag, the lack of bone response to b-PTH 1-34 was 
demonstrated by measuring cAMP levels, a metabolite 
generated in response to the action of PTH in its target tissues, 
which showed to be markedly lower in the population of dogs 
with a magnesium deficient diet. This strategy to evaluate PTH 
activity is still valid and very useful when evaluating patients 
with suspected hypoparathyroidism, as well as to establish the 
subtype of the condition (6). 
Because the adenylate cyclase activity is magnesium 
dependent, which makes it possible for chronic depletion of 
this ion to affect the activity of this enzyme. Despite the lower 
cAMP production by magnesium-deficient bone is a convincing 
explanation, it does not satisfy the fact of the reduced PTH 
synthesis in cases of magnesium-deficient bones (7). 
While most literature notes that magnesium acts as a PTH 
secretion cofactor by sensitizing the calcium receptor, it has 
also been shown that a slight reduction in serum magnesium 
concentration can stimulate PTH release; while more severe 
depletion can affect its production. These facts suggest that 
magnesium is involved, rather than in the release of the 
hormone, in its production. This phenomenon can be achieved 
by regulating the 1,25-hydroxyvitamin D synthesis, which acts 
on the vitamin D receptor (VDR) promoting the PTH mRNA 
transcription (8). 
That said, the most convincing explanation for 
hypocalcemia that occurs in magnesium depletion, is the 
reduced calcium mobilization from the bone, because of both 
the decrease in PTH levels and the action on target tissues (7). 
A similar observation to this case report was described in a 
work carried out by Chase et al. in which three patients with 
hypocalcemia due to hypomagnesemia were evaluated. All 
subjects had levels in the normal/low PTH range, markedly low 
levels of calcium and magnesium, as well as clinical signs such 
as carpal-pedal spasm. An attempt was made to modify the 
state of the patients by administering intravenous calcium, 
thereby reversing the carpal-pedal spasm and calcium levels 
were normalized, but a while after the infusion was suspended, 
calcium levels fell below normal values again. The condition 
reversed only after restoring magnesium (9). 
The previous study suggests that hypocalcemia in 
hypomagnesaemic subjects, results primarily from reduced 
magnesium and calcium exchange on bone surfaces. 
Moreover, it has been hypothesized that hypocalcemia is 
perpetuated by a lack of efficient PTH secretion in response to 
hypocalcemia and possible refractoriness to its effects on the 
bone, but not on the kidney or intestine. The first mechanism 
can be directly attributed to hypomagnesemia, while the latter 
is rather secondary to the decreased mineralization of the new 
osteoid formed secondary to hypocalcemia (9). 
In patients with hypoparathyroidism, the main 
biochemical finding is hypocalcemia with a low or 
inappropriately normal concentration of PTH. In addition, 
most hypoparathyroid patients have elevated levels of 
phosphorus, 25-hydroxyvitamin D in normal ranges, normal or 
low 1,25-hydroxyvitamin D, elevated creatinine levels and 
magnesium in normal or low range (10). 
Normal levels of 25-hydroxyvitamin D and 1,25-
hydroxyvitamin D, low PTH levels (essential for the 
hydroxylation of vitamin D in the kidney to convert it to its 
active form: 1,25-hydroxyvitamin D) and the depletion of 
magnesium, which is involved in the correct action of these 
hormones, explain why the administration of calciotropic 
hormones without the replacement of magnesium does not 
reverse hypocalcemia. It has also been demonstrated both low 
PTH secretion and elevated catabolism in the liver and kidneys 
in cases of hypomagnesemia (11). 
It has also been proposed that magnesium acts as a 
cofactor of the enzyme 25-hydroxyvitamin D-1 α-hydroxylase, 
which explains that the PTH administration in situations of 
hypomagnesemia fails to properly raise the levels of 1,25-
hydroxyvitamin D (12). 
There are certain risk factors for developing hypocalcemia 
and hypomagnesemia after a total thyroidectomy: age (> 40 
years), female sex, hyperthyroidism (hyperthyroid patients 
have been shown to have low magnesium levels, as well as 
increased urinary excretion of magnesium), greater extent of 
surgery, postoperative PTH < 8 pg/ml, postoperative 
magnesium <1.8 mg/dl, low preoperative levels of vitamin D 
and hemodilution (2). 
Other situations related to hypomagnesemia are the 
consumption of proton pump inhibitors, since the reduction in 
stomach acidity decreases the absorption of magnesium, and 
teriparatide (PTH analogous) administration, documented in 
osteoporotic patients, which results paradoxical since this 
drug has been used successfully to treat post-surgical 
hypoparathyroidism severe cases (13-15). 
PTH stimulates the magnesium reabsorption in the kidney 
and small intestine, and also causes the magnesium release 
from the bone by enhancing osteoclastic activity. These 
actions result in an increase in serum magnesium levels. In the 
setting of hypoparathyroidism, absence or low PTH circulating 
levels lead to hypocalcemia by impairing osteoclast activity, 
which diminishes the calcium efflux from bone, by enhancing 
urinary calcium excretion and by inhibiting the renal synthesis 
of calcitriol, which impairs the intestinal absorption of dietary 
calcium (10,16). 
Calcium and phosphate homeostasis is also regulated by 
fibroblast growth factor 23 (FGF23), an osteocyte-derived 
hormone that inhibits renal tubular phosphate reabsorption 
and the renal synthesis of calcitriol. Deficiency of PTH also 
causes hyperphosphatemia, owing to an increase in the renal 
tubular reabsorption of phosphate (10). Hyperphosphatemia is 
relevant since, by itself, is related to long-term complications 
seen in hypoparathyroidism such as central nervous system 
calcifications, and directly diminish PTH secretion by altering 
the response of the calcium-sensing receptor (17,18). 
Some authors emphasize the importance of postoperative 
measurement of PTH and the fact that a decrease in their levels 
can predict the development of hypocalcemia due to 
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thyroidectomy (19). When symptoms occur after 
thyroidectomy, both calcium and magnesium should be 
corrected and monitored (20). Thus, the measurement of 
calcium, magnesium, PTH and thyroid hormones is proposed 
in patients with risk factors who will undergo surgery. Auto-
transplantation of inferior parathyroid glands must always be 
considered, because it provides lower incidence of permanent 
hypoparathyroidism (21). 
CONCLUSIONS 
Hypocalcemia is a frequent complication in radical 
thyroidectomy. It is thus said that magnesium plays a crucial 
role in calcium homeostasis, both in healthy subjects and in the 
postoperative period. 
The mechanisms involved in hypocalcemia due to 
magnesium depletion are diverse and not yet well understood, 
among which are: defect in the production and secretion of 
PTH, decreased enzyme activity such as the enzyme 25-
hydroxyvitamin D-1 α- hydroxylase involved in the regulation 
of calciotropic hormones, displacement of calcium from the 
extracellular medium to the bone, reduced bone turnover, 
increased PTH catabolism and resistance to the PTH action in 
target tissues (Figure 1). 
It has also been proposed that hypomagnesemia is both a 
cause and a consequence of hypocalcemia due to the actions 
that PTH has on the homeostasis of this ion.  
Risk factors to develop hypomagnesemia and 
hypocalcemia after thyroidectomy have been identified, such 
as; age over 40 years; female gender; hypothyroidism; 
hyperthyroid patients have increased urinary excretion of 
magnesium; chronic consumption of proton pump inhibitors, 
and consumption of teriparatide. 
It is necessary to measure and keep a constant monitoring 
of magnesium values before and after surgery to intervene on 
time and avoid hypocalcemic states, especially in patients with 
risk factors. 
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